Bain Capital Life Sciences
VC Fund
Boston, United States
Bain Capital Life Sciences is a VC fund in Boston focused on Biotechnology and Health Care. Bain Capital Life Sciences specializes in buyouts, inflexion capital, growth capital, turnaround investments, and private equity. It invests in pharmaceutical, biotechnology, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that both drive medical innovation across the value chain and enablethat innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of the Bain Capital Life Sciences team enables it to deliver targeted capital and value-added strategic support to companies around critical phases of growth and inflexions in value.
- Total investments:
- 118
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Bain Capital Life Sciences invests in
Stages Bain Capital Life Sciences invests in
Countries Bain Capital Life Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Hack
|
|||
Benjamin Lund
|
|||
Coleman Mark
|
|||
|
Eric Kriss
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Biotechnology 64 (54%)
- Health Care 51 (43%)
- Medical 33 (28%)
- Therapeutics 31 (26%)
- Pharmaceutical 28 (24%)
Stage
- Post-IPO Equity 27 (23%)
- Series B 18 (15%)
- Series C 16 (14%)
- Series A 13 (11%)
- Series D 8 (7%)
Country
- United States 68 (58%)
- Germany 2 (2%)
- China 1 (1%)
- Israel 1 (1%)
- South Korea 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Koppel
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
|
Andrew Hack
Managing Director
|
Managing Director | Total investments: 9 | Find email | |
|
Benjamin Lund
Partner
|
Partner | Total investments: 3 | Find email | |
|
Coleman Mark
Founder
|
Founder | Total investments: 0 | Find email | |
|
Eric Kriss
Founder
|
Founder | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tarsus Pharmaceuticals
|
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $125M / Post-IPO Equity / Aug 06, 2026 | |
Processa Pharmaceuticals
|
Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M / Post-IPO Equity / Jul 29, 2026 | |
Freenome
|
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M / Post-IPO Equity / Jul 20, 2026 | |
CereVasc
|
CereVasc is a medical device company that develops treatments for neurological diseases, with a primary focus on communicating hydrocephalus. The company is advancing the eShunt® System, an investigational device designed to manage cerebrospinal fluid through a minimally invasive endovascular approach rather than traditional open neurosurgery. Itstechnology includes an implantable cerebrospinal fluid shunt and associated delivery components intended to treat hydrocephalus while reducing the need for invasive surgical procedures. CereVasc conducts clinical studies to evaluate the safety and effectiveness of the eShunt System in patients with conditions such as normal pressure hydrocephalus and other forms of communicating hydrocephalus. The company’s work centers on developing device-based therapies that improve access to treatment for patients with neurological disorders. | $85M / Series C / Jun 04, 2026 | |
Rapid Micro Biosystems
|
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $32M / Post-IPO Equity / May 19, 2026 | |
Cabaletta Bio
|
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy Bcells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects. | $150M / Post-IPO Equity / May 04, 2026 | |
Imperative Care
|
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M / Convertible Note / Mar 17, 2026 | |
Solid Biosciences
|
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $240M / Post-IPO Equity / Mar 06, 2026 | |
Syremis Therapeutics
|
Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders. | $165M / Series A / Dec 18, 2025 | |
C4 Therapeutics
|
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $125M / Post-IPO Equity / Oct 16, 2025 | |
| See all 118 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bain Capital Life Sciences invest in?
Bain Capital Life Sciences invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 118 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bain Capital Life Sciences?
Public channels for Bain Capital Life Sciences include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bain Capital Life Sciences?
The team at Bain Capital Life Sciences includes Adam Koppel (Managing Director), Andrew Hack (Managing Director) and Benjamin Lund (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
